This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting phosphodiesterase 10 (PDE10)] by EVP-6308.

Inclusion Criteria:

• Healthy male or female volunteers, 18 to 50 years of age

Exclusion Criteria:

• Clinically significant abnormalities on physical examination, medical history, ECG , vital signs, laboratory values, or unstable medical or psychiatric illness
• Any disorder that may interfere with drug absorption.
• Clinically significant allergy or sensitivity to medications Positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C antibody.
• Pregnant or breast feeding.
• History of exposure to any radiation >15 mSv/year (e.g., occupational or radiation therapy) over the past year.